References
- Cohen J. A., Oosterbaan R. A., Berends F. Organophosphorus compounds. Methods in Enzymology 1967; 11: 686–702
- Ellard G. A. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clinical Pharmacology and Therapeutics 1976; 19: 610–625
- Jacqz E., Hall S. D., Branch R. A. Genetically determined polymorphisms in drug oxidation. Hepatology 1986; 6: 1020–1032
- Kusano K., Tanaka S., Abe Y., Ida S., Yuzuriha T. Pharmacokinetics of a new thienodiazepine platelet activator receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in rhesus monkeys?. Xenobiotica 1993a, in press
- Kusano K., Tanaka S., Kosaki T., Miyazawa S., Tadano K., Yuzuriha T. Pharmacokinetic studies of (S)-(+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido-[4′,3′:4,5]-thieno-[3,2-f]-[1,2,4]-triazolo-[4,3-a]-[1,4]-diazepine (E6123) (I): absorption, distribution, metabolism, excretion and identification of metabolites in beagle dogs. Xenobiotic Metabolism and Disposition 1993b; 8: 73–89
- Lowry O. H., Rosebrough A. L., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
- Miyazawa S., Okano K., Kusano Tadano K. K., Tanaka S., Yuzuriha T., Machida Y., Yamatsu I. Synthesis of 14C-labelled (S)-(+)-6-(2-chlorophenyi)-3-cyclopropanecarbonyl-8, 11-dimethyl-2, 3, 4, 5-tetrahydro-8H-pyrido-[4′, 3′: 4, 5]-thieno-[3, 2-f]-[1,2,4]-triazolo-[4,3-a]-[1,4]-diazepine (14C-E6123). Journal of Labelled Compounds and Radiopharmaceuticals 1991; 29: 1073–1077
- Miyazawa S., Okano K., Shimomura N., Kawahara T., Asano O., Yoshimura H., Kawai T., Souda S., Yoshida Y., Sato T., Machida Y., Yamatsu I. A practical synthesis of optically active platelet-activating factor antagonist, (+)-6-(2-chlorophenyl)-3-cyclopropanecarbonyl-8,11-dimethyl-2,3,4,5-tetrahydro-8H-pyrido-[4′,3′: 4,5]-thieno-[3,2-f]-[1,2,4]-triazolo-[4,3-a]-[1,4]-diazepine, and its absolute configuration. Chemical and Pharmaceutical Bulletin 1992; 40: 521–523
- Rowat A. K. Genetic aspects of ethanol disposition and dependence. Neurobehavioral Toxicology and Teratology 1983; 5: 198–199
- Sakuma Y., Muramoto K., Harada S., Katayama S., Tsunoda H., Katayama K. Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice. Prostaglandins 1991b; 42: 541–555
- Sakuma Y., Tsunoda Shirato H. M., Katayama S., Yamatsu I., Katayama K. Pharmacological effects of oral E6123, a novel PAF antagonist, on biological changes induced by PAF inhalation in guinea pigs. Prostaglandins 1991a; 42: 463–472
- Tsunoda H., Sakuma Y., Harada K., Muramoto K., Katayama S., Horie T., Shimomura M., Clark R., Miyazawa S., Okano K., Machida Y., Katayama K., Yamatsu I. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Arzneimittel-Forschung/Drug Research 1990; 40: 1201–1205
- Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (MULTI) for microcomputer. Journal of Pharmacobio-Dynamics 1981; 4: 879–885